RS110504A - Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation - Google Patents

Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation

Info

Publication number
RS110504A
RS110504A YUP-1105/04A YUP110504A RS110504A RS 110504 A RS110504 A RS 110504A YU P110504 A YUP110504 A YU P110504A RS 110504 A RS110504 A RS 110504A
Authority
RS
Serbia
Prior art keywords
heme
nitric oxide
products
pharmaceutical use
degradation
Prior art date
Application number
YUP-1105/04A
Other languages
English (en)
Inventor
Leo Otterbein
Fritz Bach
Original Assignee
University Of Pittsburgh Of The Commonwealth System Of Higher Education,
Beth Isreal Deaconess Medical Center Inc.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Pittsburgh Of The Commonwealth System Of Higher Education,, Beth Isreal Deaconess Medical Center Inc., filed Critical University Of Pittsburgh Of The Commonwealth System Of Higher Education,
Publication of RS110504A publication Critical patent/RS110504A/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)

Abstract

Predmetni pronalazak se odnosi na lečenje poremećaja, korišćenjem azot monoksida (NO), hem oksigenaze-1 (HO-1) i proizvoda hema, kao što su ugljen monoksid (CO), biliverdin, bilirubin i gvoždje.
YUP-1105/04A 2002-06-21 2003-06-20 Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation RS110504A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39045702P 2002-06-21 2002-06-21
PCT/US2003/019609 WO2004000368A1 (en) 2002-06-21 2003-06-20 Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation

Publications (1)

Publication Number Publication Date
RS110504A true RS110504A (en) 2007-02-05

Family

ID=30000561

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-1105/04A RS110504A (en) 2002-06-21 2003-06-20 Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation

Country Status (13)

Country Link
US (2) US20040131703A1 (sr)
EP (1) EP1515753A4 (sr)
JP (1) JP2005533812A (sr)
CN (1) CN1674942A (sr)
AU (1) AU2003279236B8 (sr)
CA (1) CA2490392A1 (sr)
EA (1) EA200500062A1 (sr)
HR (1) HRP20041204A2 (sr)
MX (1) MXPA04012863A (sr)
NO (1) NO20050011L (sr)
PL (1) PL375161A1 (sr)
RS (1) RS110504A (sr)
WO (1) WO2004000368A1 (sr)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8128963B2 (en) * 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
US20070086954A1 (en) * 1998-11-23 2007-04-19 Miller Christopher C Method and apparatus for treatment of respiratory infections by nitric oxide inhalation
CA2254645A1 (en) * 1998-11-23 2000-05-23 Pulmonox Medical Corporation Method and apparatus for treatment of respiratory infections by nitric oxide inhalation
US7678390B2 (en) 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
US7516742B2 (en) * 1999-11-24 2009-04-14 Cardinal Health 207, Inc. Method and apparatus for delivery of inhaled nitric oxide to spontaneous-breathing and mechanically-ventilated patients with intermittent dosing
US6432077B1 (en) * 2000-12-26 2002-08-13 Sensormedics Corporation Device and method for treatment of surface infections with nitric oxide
US7122018B2 (en) * 2000-12-26 2006-10-17 Sensormedics Corporation Device and method for treatment of wounds with nitric oxide
ATE413883T1 (de) * 2001-06-21 2008-11-15 Beth Israel Hospital Kohlenmonoxid verbessert die ergebnisse bei gewebe- und organtransplantationen und unterdrückt apoptose
WO2003066067A2 (en) * 2002-02-04 2003-08-14 Alfama - Investigaçao E Desenvolvimento De Produtos Farmaceuticos Lda. Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases
MXPA04010243A (es) 2002-04-15 2005-07-05 Univ Pittsburgh Metodos para tratar ileo.
US8097585B2 (en) 2002-04-15 2012-01-17 Beth Israel Deaconess Medical Center, Inc. Methods of treating inflammation by administration of heme oxygenase-1 and products of heme degradation
EP1499328B1 (en) 2002-04-15 2015-09-16 University of Pittsburgh - Of the Commonwealth System of Higher Education Methods of treating necrotizing enterocolitis
EP1505990B1 (en) * 2002-05-17 2011-08-24 Yale University Methods of treating hepatitis
MXPA04012167A (es) * 2002-06-05 2005-09-21 Univ Yale Metodos para tratar angiogenesis, crecimeinto tumoral y metastasis.
US7531133B2 (en) * 2002-09-10 2009-05-12 Pulmonox Technologies Corporation Use of nitric oxide gas in an extracorporeal circuitry to treat blood plasma
DE10249552A1 (de) 2002-10-23 2004-05-13 Vifor (International) Ag Wasserlösliche Eisen-Kohlenhydrat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel
AU2003283982A1 (en) * 2002-11-07 2004-06-03 University Of Pittsburgh Of The Commonwealth System Of High Education Treatment for hemorrhagic shock
US20070117769A1 (en) * 2003-09-29 2007-05-24 Maines Mahin D Methods of modulating cell cycle and cell signaling pathways using biliverdin reductase
WO2005077005A2 (en) * 2004-02-04 2005-08-25 The General Hospital Corporation Enhancing the effectiveness of an inhaled therapeutic gas
EP1755715A4 (en) * 2004-05-11 2010-03-24 Sensormedics Corp INTERMITTENT DETERMINATION OF GASEOUS NITRIC OXIDE
US8518457B2 (en) * 2004-05-11 2013-08-27 Pulmonox Technologies Corporation Use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant
US20070154570A1 (en) * 2004-09-29 2007-07-05 Miller Christopher C Use of nitric oxide in the treatment and disinfection of biofilms
MX2007013196A (es) * 2005-04-20 2008-01-18 Hutchinson Fred Cancer Res Metodos, composiciones y articulos de fabricacion para mejorar la supervivencia de celulas, tejidos, organos y organismos.
US20090214618A1 (en) 2005-05-27 2009-08-27 Schoenfisch Mark H Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
MX2008004284A (es) * 2005-09-30 2008-10-23 Ovation Pharmaceuticals Inc Metodo para tratar pancreatitis.
WO2007057763A2 (en) * 2005-11-18 2007-05-24 Pulmonox Technologies Corporation Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant
WO2007073005A1 (ja) * 2005-12-22 2007-06-28 Keio University メチル基転移反応調節物質
WO2007073006A1 (ja) * 2005-12-22 2007-06-28 Keio University 細胞保護性を有するアミノ酸の増加誘導剤及び増加方法
CA2635894C (en) 2006-01-06 2017-09-12 Luitpold Pharmaceuticals, Inc. Methods and compositions for administration of iron
US8790715B2 (en) 2006-02-16 2014-07-29 Ino Therapeutics Llc Method and apparatus for generating nitric oxide for medical use
WO2007103427A2 (en) * 2006-03-06 2007-09-13 Wang Xiang H Medical use of bilirubin and its structural analogues
JP5020525B2 (ja) * 2006-03-30 2012-09-05 財団法人生産開発科学研究所 配位子置換型輸液製剤
GB0613362D0 (en) * 2006-07-05 2006-08-16 Hemocorm Ltd Therapeutic delivery of carbon monoxide
WO2008008513A2 (en) * 2006-07-13 2008-01-17 Beth Israel Deaconess Medical Center Inc. Combination treatments
WO2008048514A2 (en) * 2006-10-13 2008-04-24 Nitric Biotherapeutics, Inc. Topical nitric oxide as a treatment of autoimmune diseases
US8079998B2 (en) * 2006-10-20 2011-12-20 Pulmonox Technologies Corporation Methods and devices for the delivery of therapeutic gases including nitric oxide
US20080193566A1 (en) * 2007-02-09 2008-08-14 Miller Christopher C Use of high dose concentrations of gaseous nitric oxide
US20100196516A1 (en) * 2007-04-24 2010-08-05 ALFAMA-Investigacao e Desenvolvimento de produtos Farmaceuticos, Lda Treatment of infections by carbon monoxide
JP2010530001A (ja) * 2007-06-15 2010-09-02 イカリア， インコーポレイテッド 硫化物単独または一酸化窒素との組み合わせを含む組成物およびその使用
EP2182961B1 (en) * 2007-07-24 2012-05-02 Alfama - Investigaçao e Desenvolvimento de Productos Farmaceuticos LDA. Prevention of gastric ulcery by carbon monoxide
EP2445508B1 (en) 2009-06-22 2018-11-14 VERO Biotech LLC Nitric oxide therapies
CA2771308C (en) 2009-08-21 2020-01-21 Novan, Inc. Topical gels comprising nitric oxide releasing polysiloxane macromolecules
CA2771389C (en) 2009-08-21 2019-04-09 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
EP2519297A4 (en) 2009-12-31 2013-08-21 Univ Ohio SYSTEMS AND METHODS FOR PROMOTING HEALING
CN102762101B (zh) * 2010-02-18 2014-09-17 高点制药有限责任公司 取代的稠合咪唑衍生物、药物组合物及其使用方法
WO2012050874A2 (en) * 2010-09-28 2012-04-19 Soares Miguel P Targeting heme for the treatment of immune mediated inflammatory diseases
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
WO2012118829A2 (en) 2011-02-28 2012-09-07 Novan, Inc. Tertiary s-nitrosothiol-modified nitricoxide-releasing xerogels and methods of using the same
BR112013023740A2 (pt) 2011-03-16 2016-08-02 Dynasil Biomedical Corp métodos e materiais para prolongamento da armazenagem útil de preparações de glóbulo vermelho e preparações de plaqueta
US9163044B2 (en) 2011-04-19 2015-10-20 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof
JP6134710B2 (ja) 2011-07-21 2017-05-24 アルファーマ インコーポレイテッドＡｌｆａｍａ，Ｉｎｃ． 一酸化ルテニウム放出分子およびその使用
US9987302B2 (en) 2011-08-09 2018-06-05 Beth Israel Deaconess Medical Center, Inc. Methods of treating DNA damage
US9763899B2 (en) 2012-08-30 2017-09-19 The Board Of Trustees Of The Leland Stanford Junior University Iron chelators and use thereof for reducing transplant failure during rejection episodes
TW201618795A (zh) * 2014-04-15 2016-06-01 波泰里斯股份有限公司 用以改良器官功能及延長器官移植物壽命之系統及方法
US10314860B2 (en) 2015-05-21 2019-06-11 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating and preventing venom related poisoning
CN105727379A (zh) * 2016-02-25 2016-07-06 顾宇春 血红素加氧酶药物洗脱支架
CN105748485A (zh) * 2016-03-28 2016-07-13 暨南大学 亚铁原卟啉在制备预防和治疗急性co中毒的药物的应用
KR101962518B1 (ko) * 2016-09-13 2019-03-26 울산대학교 산학협력단 일산화탄소 또는 일산화탄소 공급체를 유효성분으로 함유하는 아세트아미노펜 유도 간 독성 예방 또는 치료용 조성물
US20180169142A1 (en) * 2016-12-19 2018-06-21 Nobilis Therapeutics, Inc. Methods, means and compositions for improving outcomes of surgical interventions and inflammatory sequel
WO2019090075A1 (en) * 2017-11-02 2019-05-09 Ait Therapeutics, Inc. Inhalation of nitric oxide
AU2018360849A1 (en) * 2017-11-02 2020-05-28 Beyond Air, Inc. Inhalation of nitric oxide
CN110038014A (zh) * 2019-04-18 2019-07-23 上海康孕企业管理合伙企业（有限合伙） 血红素在改善夜间尿频的药物、食品及保健食品中的应用
US20230140515A1 (en) * 2021-11-03 2023-05-04 Baxter International Inc. Nitric oxide donors for use in surgical recovery
KR20240015199A (ko) * 2022-07-26 2024-02-05 한양대학교 산학협력단 간／지방조직 이중 표적 복합 나노 약물 전달체

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4053590A (en) * 1975-02-27 1977-10-11 Alza Corporation Compositions of matter comprising macromolecular hemoglobin
US4264739A (en) * 1979-01-05 1981-04-28 Merck & Co., Inc. Sparger for cell culture system
US5240912A (en) * 1983-05-09 1993-08-31 Todaro George J Transforming growth factor (TGF) peptides
US4979939A (en) * 1984-05-14 1990-12-25 Surgical Systems & Instruments, Inc. Atherectomy system with a guide wire
US5084380A (en) * 1985-01-29 1992-01-28 Applied Biotechnology Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins
US5449665A (en) * 1985-09-24 1995-09-12 Item Development Aktiebolag Continuous intravenous infusion of adenosine to human patients undergoing percutaneous transluminal angioplasty
DE3739650C1 (de) * 1987-11-23 1989-05-24 Immuno Ag Fermenter zum Zuechten von Zellkulturen
US5180366A (en) * 1990-10-10 1993-01-19 Woods W T Apparatus and method for angioplasty and for preventing re-stenosis
US5792325A (en) * 1990-11-15 1998-08-11 Richardson, Jr.; William H. Electric arc material processing system
WO1992010228A1 (en) * 1990-12-05 1992-06-25 The General Hospital Corporation Devices for treating pulmonary vasoconstriction and asthma
US5570683A (en) * 1990-12-05 1996-11-05 The General Hospital Corporation Methods and devices for treating pulmonary vasoconstriction and asthma
US5293875A (en) * 1992-06-16 1994-03-15 Natus Medical Incorporated In-vivo measurement of end-tidal carbon monoxide concentration apparatus and methods
US5731526A (en) * 1992-09-23 1998-03-24 Kindrick; Dudley R. System for displaying the amount of fluid dispensed from a hand-held sprayer
DK0693924T4 (da) * 1993-02-22 2008-08-04 Abraxis Bioscience Inc Fremgangsmåde til (in vivo) levering af biologiske materialer og sammensætninger, der er egnede dertil
US5985307A (en) * 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US5523092A (en) * 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5763431A (en) * 1993-08-20 1998-06-09 Jackson; Meyer B. Method for regulating neuropeptide hormone secretion
US5588962A (en) * 1994-03-29 1996-12-31 Boston Scientific Corporation Drug treatment of diseased sites deep within the body
DE4421433C1 (de) * 1994-06-18 1995-06-08 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Wirkstoffen, die Kohlenmonoxid-Quellen darstellen, Verfahren zu seiner Herstellung und seine Verwendung
US5476764A (en) * 1994-09-16 1995-12-19 The Regents Of The University Of California Method using CO for extending the useful shelf-life of refrigerated red blood cells
US6066333A (en) * 1994-09-22 2000-05-23 William Harvey Research Limited Pharmaceutical control of inflammation
US5664563A (en) * 1994-12-09 1997-09-09 Cardiopulmonary Corporation Pneumatic system
US5914316A (en) * 1994-12-16 1999-06-22 Washington University Method of inhibiting intimal hyperplasia
US6063407A (en) * 1995-02-16 2000-05-16 The General Hospital Corporation Treatment of vascular thrombosis and restenosis with inhaled nitric oxide
US5712293A (en) * 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
FR2735382B1 (fr) * 1995-06-15 1997-07-25 Air Liquide Installation de production de monoxyde de carbone incorporant une unite de separation cryogenique
DE19535781C2 (de) * 1995-09-26 1999-11-11 Fraunhofer Ges Forschung Vorrichtung zur aktiven Strömungsunterstützung von Körperflüssigkeiten
DK0914103T3 (da) * 1996-04-05 2006-10-23 Gen Hospital Corp Behandling af hæmoglobinopati
US6069132A (en) * 1996-08-14 2000-05-30 Revanker; Ganapathi R. Phosphazole compounds
WO1998007447A1 (en) * 1996-08-23 1998-02-26 Algos Pharmaceutical Corporation Anticonvulsant containing composition for treating neuropathic pain
US8128963B2 (en) * 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
US6316403B1 (en) * 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
US6436365B2 (en) * 1997-09-23 2002-08-20 Schering Aktiengesellschaft Process for therapeutic treatment of proliferative diseases
US6656452B1 (en) * 1997-10-21 2003-12-02 The General Hospital Corporation Use of inhaled NO as anti-inflammatory agent
US6251418B1 (en) * 1997-12-18 2001-06-26 C.R. Bard, Inc. Systems and methods for local delivery of an agent
US6450989B2 (en) * 1998-04-27 2002-09-17 Artemis Medical, Inc. Dilating and support apparatus with disease inhibitors and methods for use
US6203991B1 (en) * 1998-08-21 2001-03-20 The Regents Of The University Of Michigan Inhibition of smooth muscle cell migration by heme oxygenase I
US7678390B2 (en) * 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
US20050250688A1 (en) * 1999-04-01 2005-11-10 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
US6142067A (en) * 1999-04-06 2000-11-07 Roth; Eldon Apparatus for treating ammoniated meats
US20040038192A1 (en) * 1999-04-14 2004-02-26 Breonics, Inc. System for exsanguinous metabolic support of an organ or tissue
US7632803B2 (en) * 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
SE9903985D0 (sv) * 1999-11-03 1999-11-03 Aga Ab Use of nitric oxide
US6811965B2 (en) * 2000-03-08 2004-11-02 Yoram Vodovotz Kidney perfusion solution containing nitric oxide donor, inhibitor of NOS2, glutathione, gluconate and methods of use
US6508784B1 (en) * 2000-05-19 2003-01-21 Yan-Ho Shu Balloon catheter having adjustable centering capabilities and methods thereof
US6601580B1 (en) * 2000-06-28 2003-08-05 The General Hospital Corporation Enhancing therapeutic effectiveness of nitric oxide inhalation
FR2812197B1 (fr) * 2000-07-27 2003-01-03 Air Liquide Sante Int Utilisation de co dans le traitement de l'inflammation des voies aeriennes superieures ou des bronches
FR2816212A1 (fr) * 2000-11-03 2002-05-10 Air Liquide Sante Int Utilisation de monoxyde de carbone (co) dans le traitement des inflammations du systeme cardiovasculaire
WO2002080859A2 (en) * 2001-03-20 2002-10-17 Glaxo Group Limited Inhalation drug combinations
MXPA03008820A (es) * 2001-03-30 2004-07-30 Sangstat Medical Corp Compuestos generadores de monoxido de carbono, para el tratamiento de desordenes vasculares, inflamatorios e inmunologicos.
GB0111872D0 (en) * 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
EP1395241B9 (en) * 2001-05-25 2005-06-15 Medtronic, Inc. Implantable medical device with controllable gaseous agent release system
ATE413883T1 (de) * 2001-06-21 2008-11-15 Beth Israel Hospital Kohlenmonoxid verbessert die ergebnisse bei gewebe- und organtransplantationen und unterdrückt apoptose
CA2475963A1 (en) * 2002-02-13 2003-09-04 Beth Israel Deaconess Medical Center, Inc. Methods of treating vascular disease
JP2005537223A (ja) * 2002-04-05 2005-12-08 ニトロメッド，インク． 酸化窒素供与体、組成物および使用法
EP1499328B1 (en) * 2002-04-15 2015-09-16 University of Pittsburgh - Of the Commonwealth System of Higher Education Methods of treating necrotizing enterocolitis
US8097585B2 (en) * 2002-04-15 2012-01-17 Beth Israel Deaconess Medical Center, Inc. Methods of treating inflammation by administration of heme oxygenase-1 and products of heme degradation
MXPA04010243A (es) * 2002-04-15 2005-07-05 Univ Pittsburgh Metodos para tratar ileo.
EP1505990B1 (en) * 2002-05-17 2011-08-24 Yale University Methods of treating hepatitis
MXPA04012167A (es) * 2002-06-05 2005-09-21 Univ Yale Metodos para tratar angiogenesis, crecimeinto tumoral y metastasis.
AU2003283982A1 (en) * 2002-11-07 2004-06-03 University Of Pittsburgh Of The Commonwealth System Of High Education Treatment for hemorrhagic shock
AU2003293529A1 (en) * 2002-12-16 2004-07-29 Nitromed, Inc. Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
WO2005077005A2 (en) * 2004-02-04 2005-08-25 The General Hospital Corporation Enhancing the effectiveness of an inhaled therapeutic gas

Also Published As

Publication number Publication date
AU2003279236B2 (en) 2009-01-22
HRP20041204A2 (en) 2005-06-30
EP1515753A4 (en) 2009-07-15
US20080171021A1 (en) 2008-07-17
JP2005533812A (ja) 2005-11-10
EP1515753A1 (en) 2005-03-23
CN1674942A (zh) 2005-09-28
EA200500062A1 (ru) 2005-06-30
AU2003279236B8 (en) 2009-02-19
NO20050011L (no) 2005-03-18
PL375161A1 (en) 2005-11-28
MXPA04012863A (es) 2005-03-31
AU2003279236A1 (en) 2004-01-06
US20040131703A1 (en) 2004-07-08
WO2004000368A1 (en) 2003-12-31
CA2490392A1 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
RS110504A (en) Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation
EP1401479A4 (en) DETECTION AND THERAPY OF VULNERABLE PLATES USING PHOTODYNAMIC COMPOUNDS
TW200608979A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
SG164368A1 (en) Treatment of cancer
NO20052348L (no) Behandling av hemoragisk sjokk
YU20050003A (sh) Postupak i uređaj za davanje co
RS91004A (en) Methods of treating ileus
PH12013500123A1 (en) Hemiasterlin derivatives and uses thereof
EA200401525A1 (ru) Способы лечения гепатита (варианты )
UA86570C2 (ru) Способ лечения некротизирующего энтероколита
WO2003088748A8 (en) Use of heme oxygenase-1 and products of heme degradation
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
EP1392328A4 (en) ANTICANCER THERAPY
WO2002094189A3 (en) Compositions and methods for treating or preventing convulsions or seizures
HK1081862A1 (en) Synergistic combination comprising roflumilast and (r,r)-formoterol
HK1079116A1 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and radiotherapy
AU4779599A (en) Methods of inhibiting (helicobacter pylori)
WO2008008513A3 (en) Combination treatments
EP1417968A3 (en) Antitumour compositions containing propolis and resveratrol
BG106259A (en) Means for the treatment of burns